Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vesigel by UroGen Pharma for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Vesigel is under clinical development by UroGen Pharma and currently in Phase III for Non Muscle Invasive Bladder Cancer (NMIBC)...
TLD-1433 by Theralase Technologies for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
TLD-1433 is under clinical development by Theralase Technologies and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
Resiquimod by SURGE Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Resiquimod is under clinical development by SURGE Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
TARA-002 by Protara Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
TARA-002 is under clinical development by Protara Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...